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Despite the ﬁdelity of host cell polymerases, the human papillomavirus (HPV) displays a degree of geno-
mic polymorphism resulting in distinct genotypes and intra-type variants. The current HPV vaccines tar-
get the most prevalent genotypes associated with cervical cancer (HPV16/18) and genital warts (HPV6/
11). Although these vaccines confer some measure of cross-protection, a multivalent HPV vaccine is in
the pipeline that aims to broaden vaccine protection against other cervical cancer-associated genotypes
including HPV31, HPV33, HPV45, HPV52 and HPV58. Both current and next generation vaccines comprise
virus-like particles, based upon the major capsid protein, L1, and vaccine-induced, type-speciﬁc protec-
tion is likely mediated by neutralizing antibodies targeting L1 surface-exposed domains.
The aim of this study was to perform an in silico analysis of existing full length L1 sequences represent-
ing vaccine-relevant HPV genotypes in order to address the degree of naturally-occurring, intra-type
polymorphisms. In total, 1281 sequences from the Americas, Africa, Asia and Europe were assembled.
Intra-type entropy was low and/or limited to non-surface-exposed residues for HPV6, HPV11 and
HPV52 suggesting a minimal effect on vaccine antibodies for these genotypes. For HPV16, intra-type
entropy was high but the present analysis did not reveal any signiﬁcant polymorphisms not previously
identiﬁed. For HPV31, HPV33, HPV58, however, intra-type entropy was high, mostly mapped to sur-
face-exposed domains and in some cases within known neutralizing antibody epitopes. For HPV18 and
HPV45 there were too few sequences for a deﬁnitive analysis, but HPV45 displayed some degree of sur-
face-exposed residue diversity. In most cases, the reference sequence for each genotype represented a
minority variant and the consensus L1 sequences for HPV18, HPV31, HPV45 and HPV58 did not reﬂect
the L1 sequence of the currently available HPV pseudoviruses. These data highlight a number of variant
amino acid residues that warrant further investigation for vaccine and natural history studies of HPV.
 2013 The Authors. Published by Elsevier B.V. Open access under CC BY license.1. Introduction contains VLP representing HPV6 and HPV11 which are associatedCervical cancer is the third most common cancer of women,
accounting for an estimated 530,000 cases and 275,000 deaths
per annum worldwide (Arbyn et al., 2011). Although there are
some geographical differences, human papillomavirus (HPV) geno-
types HPV16 and HPV18 are associated with approximately 70% of
cervical cancer cases (Li et al., 2010). Virus-like particle (VLP) vac-
cines (Cervarix and Gardasil) based on the major capsid (L1) pro-
teins of HPV16 and HPV18 have demonstrated almost 100%
efﬁcacy against high grade lesions associated with these two types
in clinical trials (Lu et al., 2011; Romanowski, 2011). Gardasil alsowith the development of genital warts.
Serological assays for the evaluation of vaccine antibody re-
sponses and natural history studies of HPV infection include com-
petitive and direct immunoassays (Dias et al., 2005; Giannini et al.,
2006) and a pseudovirus-based neutralization assay (Pastrana
et al., 2004). All these systems have potential shortcomings that af-
fect their utility in monitoring vaccine-induced antibody responses
(Schiller et al., 2012). However, the detection of high titer, type-
speciﬁc neutralizing antibodies in the serum and cervico-vaginal
secretions of human vaccinee (Einstein et al., 2009) and anti-
body-mediated protection in animal models (Longet et al., 2011)
has led to the reasonable assumption that antibodies are the prin-
cipal mediators of type-speciﬁc vaccine-induced protection (Schil-
ler and Lowy, 2012). Type-speciﬁc seroconversion following
natural infection is less efﬁcient (Carter et al., 2000) but appears
to be associated with some degree of protection against subse-
quent infection (Lin et al., 2013).
Closely-related HPV types within the alpha-papillomavirus spe-
cies groups A9 (HPV16-like: HPV31, HPV33, HPV35, HPV52 and
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are associated with a further ca. 25% of cervical cancers worldwide,
although there are geographical differences in the relative distribu-
tion of these types (Li et al., 2010). The current generation of HPV
vaccines afford some degree of cross-protection against a few of
these types including HPV31, HPV33 and HPV45 but probably
not HPV52 and HPV58 (Lu et al., 2011; Romanowski, 2011). This
protection is at least coincident with the detection of neutralizing
antibodies in the serum of vaccinated individuals (Draper et al.,
2011; Einstein et al., 2011; Kemp et al., 2011). The limited degree
of cross-protection afforded by the current generation of VLP-
based vaccines has led to the development of a candidate next gen-
eration multivalent VLP-based vaccine to extend coverage to a
wider array of HPV types (Van de Velde et al., 2012).
Despite the excellent proof-reading ability of host cell polymer-
ases, the approximately 8 kb double-stranded DNA genome of HPV
displays a certain degree of intra-type genome polymorphism
(Chen et al., 2009, 2011). Such variants are predicted to have arisen
over millennia due to the slow evolutionary rate of the genome
(estimated to be 108 base substitutions per site per year) (Chen
et al., 2009). The extent of HPV genome diversity, the interplay be-
tween positive and negative selection pressures and genetic drift,
and the biological consequences of such variation are largely un-
clear (Bernard et al., 2006).
Serological cross-reactivity in ELISA (Cheng et al., 1995; Touze
et al., 1998) and neutralization (Pastrana et al., 2001) assays using
targets representing HPV16 variants suggested that the most com-
mon HPV16 L1 polymorphisms are unlikely to adversely inﬂuence
the effectiveness of an HPV vaccine based upon a single HPV16 L1
sequence. This hypothesis appears to have been conﬁrmed by
HPV16/18 vaccine efﬁcacy data reported from clinical trials carried
out in the Americas, Europe and the Asia–Paciﬁc region (Munoz
et al., 2010; Paavonen et al., 2007).
VLP assembly follows a step-wise process in which ﬁve L1
monomers form an intermediate structure (known as a capsomer)
and then these pentameric subunits associate to form an icosahe-
dral structure of 72 capsomers (Chen et al., 2000). The highest de-
gree of inter-type diversity is located within the external loops of
the L1 protein and is thought to contribute to the differences in
antigenicity between papillomavirus types (Bishop et al., 2007;
Chen et al., 2000). Until recently, most studies examining intra-
type variation of the major capsid protein have focussed on small
fragments of the L1 gene. More recently, a number of studies have
published full length L1 or full genome HPV sequences and conse-
quently a detailed structural picture of intra-type variation is now
possible. This study sought to perform an evaluation of worldwide
L1 amino acid diversity for a range of vaccine-relevant HPV types,
using available full length L1 sequences, and postulate upon the
impact that such polymorphisms would have on current and can-
didate L1-based vaccines.
2. Materials and methods
2.1. Source of available sequences
Reference sequence accession numbers and the taxonomy iden-
tiﬁers for each HPV type are as indicated: HPV6 (X00203;
txid31552; [6a] txid37122; [6b] txid10600), HPV11 (M14119;
txid10580), HPV16 (HPV16R: corrected version of K02718 (Myers
et al., 1995); txid333760), HPV18 (HPV18R: AY262282, corrected
version of X05015; txid333761), HPV31 (J04353; txid10585),
HPV33 (M12732; txid10586), HPV45 (X74479; txid10593),
HPV52 (X74481; txid10618) and HPV58 (D90400; txid10598) (de
Villiers et al., 2004). The reference sequences are the same as those
given in the Papillomavirus Episteme database (http://pave.niaid.-
nih.gov). Sequences were downloaded from the National Center forBiotechnology Information (NCBI; http://www.ncbi.nlm.nih.gov/)
between November and December 2012. A referenced source list
of the sequences used in this study can be found in Supplementary
Table S1. Only full length L1 sequences were considered for this
analysis. For some studies, only one sequence was deposited in
the NCBI database to represent multiple occurrences of a variant;
in these cases, the prevalence of individual variant sequences
was calculated using the numbers indicated in the relevant publi-
cation. The consensus sequence was generated from the panel of
assembled sequences for each genotype by selecting the most fre-
quent amino acid present at a given position, which may or may
not be the same as the reference sequence.
2.2. Site-speciﬁc residue variation and mapping
Sequences were aligned, translated and exported as a FASTA
formatted ﬁle using MEGA v4.1 (Tamura et al., 2007). Residue posi-
tions were numbered according to the initiating ATG codon of the
L1 protein coding sequence (CDS; http://pave.niaid.nih.gov) of the
appropriate reference sequence, according to convention (Bishop
et al., 2007; Chen et al., 2000). For example, and for the purposes
of clarity, the HPV16 L1 protein starts with the MSLWmotif. Amino
acid substitutions are designated X123Y, where X is the amino acid
at reference sequence residue position 123 that is substituted by
amino acid Y in the variant. Deletions are indicated by a D. Site-
speciﬁc Shannon entropy was determined using the aligned amino
acid sequences for each type using the Entropy One program on the
Los Alamos National Laboratory website (http://www.hiv.lanl.gov/
content/sequence/ENTROPY/entropy_one.html) (Korber et al.,
1994). For comparison purposes, a level of 5% residue variation
equates to an entropy score of ca. 0.18. Protein secondary struc-
tures (amino [Nt] and carboxy [Ct] termini, a-helices, b-sheets
and external loops [BC, DE, EF, FG, HI]) were highlighted accord-
ingly (Bishop et al., 2007). Variant residues were mapped to the
surface of the HPV16 capsomer crystal structure (PDB code:
2R5H) using Swiss-PDP viewer v4.0 (Deep View) (Guex and Pei-
tsch, 1997).
2.3. Statistical analysis
Differences in entropy between loop and non-loop residues
(non parametric, Mann–Whitney U test) and differences in propor-
tions in geographic distribution (2-tailed Fisher’s exact test) were
evaluated using Stata 12.0 (StataCorp, Tx., USA).3. Results and discussion
3.1. HPV6/11
HPV6 and HPV11 genotypes were represented by n = 136 and
n = 103 sequences, respectively, with the majority (94%) being
from Europe (Fig. 1). There were no full length sequences from
Africa and few from the Americas (2%) or Asia (4%). The reference
sequences for HPV6 and HPV11 were the same as their respective
consensus sequence and represented 76% (95% CI, 68–83%) and
86% (95% CI, 78–92%) of HPV6 and HPV11 full length L1 sequences,
respectively. In both cases, the pseudovirus L1 sequence was the
same as the consensus and the reference sequence.
HPV6 L1 sequence variation was low (Fig. 2) with 17% of se-
quences incorporating an E431Q substitution in the a4-bJ region
(Table 1). The E431Q substitution does not appear to have an im-
pact on VLP stability (Caparros-Wanderley et al., 1999). HPV6 vac-
cine antibodies are evaluated by competition with the type-
speciﬁc neutralizing monoclonal antibody (MAb) H6.M48 (Dias
et al., 2005; Smith et al., 2008). The epitope of this MAb appears
A9
HPV6 HPV11
A10
N=136 N=103
HPV16 HPV31 HPV33
N=23 N=13
HPV52 HPV58
N=58 N=205 N=465N=183 N=95
HPV18 HPV45
A7
Fig. 1. Geographical distribution of HPV full length L1 sequences. Total numbers of available full length L1 sequences for each HPV type are indicated beneath each chart.
Alpha-papillomavirus species groups are as indicated: A10 (HPV6, HPV11), A9 (HPV16, HPV31, HPV33, HPV52 and HPV58) and A7 (HPV18, HPV45). The regional proportion of
L1 sequences are colored according to the inset map: Americas (green), Europe (yellow), Africa (blue) and Asia (red).
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loop, while antibodies generated during natural infection appear
to bind to a range of epitopes (McClements et al., 2001; Orozco
et al., 2005).
HPV11 L1 sequence variation was low (Fig. 2) with 7% of se-
quences incorporating an A235S substitution in the a1 region (Ta-
ble 1). HPV11 vaccine antibodies are monitored through
competition with the type-speciﬁc neutralizing MAb K11.B2 (Dias
et al., 2005; Smith et al., 2008). The epitope of this MAb is unclear.
MAb K11.B2 replaced MAb H11.B2 during development of the
competitive assay and the epitope of this latter MAb was identiﬁed
within the DE loop (Ludmerer et al., 1996; Orozco et al., 2005).
Antibodies generated following natural infection appear to target
epitopes in the C-terminal (Ct) portion downstream of the DE loop
(Wang et al., 2003).
There were too few non-European sequences available to eval-
uate the geographical distribution of the HPV6 E431Q and HPV11
A235S variants.
3.2. HPV16, HPV31, HPV33, HPV52 and HPV58
HPV16 (n = 183), HPV52 (n = 205) and HPV58 (n = 465) were
well represented within the dataset, with HPV31 (n = 95) and
HPV33 (n = 58) less so. Each genotype was represented by se-
quences from Africa, the Americas and Asia, albeit to varying de-
grees, but European sequences were only available for HPV16
and HPV58, at 3% and 7% of the total, respectively (Fig. 1). The
available number of sequences and the degree of intra-type varia-
tion was sufﬁcient to enable mapping the entropy score of surface
exposed residues for each A9 genotype onto the crystal structure of
the HPV16 capsomer (Fig. 3).
The reference sequence for HPV16 represented only 7% (95% CI,
3–11%) of sequences. The consensus sequence differed from the
reference by a T266A substitution in the FG loop, represented
37% (95% CI, 30–44%) of sequences overall and could be found in
all four geographical regions. The HPV16 pseudovirus L1 sequence
was identical to the consensus. In addition to the T266A polymor-
phism, several variable sites within structural domains (H76Y,T389S, L475F) or within the EF (T176N, N181T), FG (S282P) and
HI (T353P) loops were found in these sequences (Fig. 2), in a vari-
ety of combinations (Supplementary Fig. S1). Surface-exposed res-
idues that exhibited the highest degree of variation did not appear
to form a distinct cluster but instead could be found dispersed
along the ridge of the EF loop and its base (adjacent to the FG/HI
loops) (Fig. 3A, 3B HPV16). The H76Y, T176N, S282P and L475F
mutations were overrepresented in sequences from Africa, while
the H76Y and L475F mutations were underrepresented in se-
quences from Asia relative to the overall mean (Table 1). The
HPV16 VLP in the Cervarix vaccine matches the consensus se-
quence, including the T266A substitution (Deschuyteneer et al.,
2010). HPV16 vaccine antibodies are monitored by competition
with the type-speciﬁc neutralizing MAb H16.V5 (Dias et al.,
2005; Giannini et al., 2006; Smith et al., 2008). This MAb targets
a conformational epitope in the FG loop, with possible contribution
from the HI loop (Carter et al., 2003) and is thought to represent a
signiﬁcant proportion, but not the entirety, of antibody speciﬁcities
produced during natural infection (Carter et al., 2003; Wang et al.,
1997). Using a series of HPV16:HPV31 loop-swap hybrid VLP,
HPV16-speciﬁc antibodies generated during natural infection ap-
peared to target the DE, FG, and HI loops (Carter et al., 2006).
The H76Y, T176N, N181T, S282P, T353P, T389S and L475F muta-
tions have been substituted into an HPV16 pseudovirus L1 back-
bone based upon the European variant 114/K (Accession no.
EU118173, identical to the consensus reported here) and found
not to have a signiﬁcant impact on recognition by antibodies elic-
ited to HPV16 (Pastrana et al., 2001). The binding and neutraliza-
tion of MAb H16.E70, however, appears to be affected by
substitutions in the FG loop, including the reciprocal A266T muta-
tion which was present in ca. 11% of sequences (Carter et al., 2003;
Roden et al., 1997; Varsani et al., 2006).
The reference sequence for HPV31 represented only 12% (95%
CI, 6–20%) of sequences and was the same as the pseudovirus
sequence. The HPV31 L1 protein exhibited variation in the a4-bJ
region (T432S in 7% of sequences) and the FG loop (T267A and
T274N; in 49% and 78% of sequences, respectively) (Fig. 2 and
Table 1), in a limited number of combinations (Supplementary
Fig. 2. Intra-type, site-speciﬁc amino acid residue entropy. Residue variation estimated using Shannon entropy, wherein a value of zero reﬂects site-speciﬁc conservation and
higher values indicate increasing degrees of site-speciﬁc variation. A level of 5% residue variation equates to an entropy score of ca. 0.18. Site-speciﬁc variation(s) above this
level are indicated by convention, numbered according to the reference sequence for that HPV type. The positions of major structural elements are indicated.
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Table 1
Summary of L1 amino acid polymorphisms.
HPV Residue Regiona Geographical regionb Total
Americas Europe Africa Asia n/N % (95%CI)
6 E431Q a4-bJ 0/2 23/131 0/3 23/136 17 (11–24)
11 A235S a1 0/2 7/93 0/8 7/103 7 (3–14)
16 H76Y bC 35/86 0/8 16/19* 12/70* 63/183 34 (28–42)
T176N EF 35/86 0/8 16/19* 13/70 64/183 35 (28–43)
N181T EF 17/86 0/8 6/19 18/70 41/183 22 (17–29)
T266A FG 68/86 8/8 16/19 70/70 162/183 89 (83–93)
S282P FG 4/86 0/8 7/19** 2/70 13/183 7 (4–12)
T353P HI 26/86 0/8 9/19 11/70 46/183 25 (19–32)
T389S a2 10/86 0/8 2/19 5/70 17/183 9 (6–14)
L475F Ct 34/86 0/8 16/19* 10/70* 60/183 33 (26–40)
31 T267A FG 46/89 1/3 0/3 47/95 49 (39–60)
T274N FG 71/89 2/3 1/3 74/95 78 (68–86)
T432S a4-bJ 7/89 0/3 0/3 7/95 7 (3–15)
33 T56N BC 18/46 3/7 4/5 25/58 43 (30–57)
G133S DE 18/46 3/7 4/5 25/58 43 (30–57)
K135R DE 2/46 0/7 1/5 3/58 5 (1–14)
T266K/N FG 20/46 3/7 5/5 28/58 48 (35–62)
G268E FG 2/46 0/7 1/5 3/58 5 (1–14)
K495R Ct 14/46 3/7 1/5 18/58 31 (20–45)
52 Q282K FG 15/127 0/1 0/76* 15/205 7 (4–12)
K355T HI 10/127 0/1 0/76 10/205 5 (2–9)
S358D/N HI 14/127 0/1 0/76* 14/205 7 (4–11)
D448E a4-bJ 13/127 0/1 0/76* 13/205 6 (3–11)
58 V118I DE 15/75 2/31 46/81*** 9/278*** 72/465 15 (12–19)
L124F DE 61/75 29/31 38/81* 205/278 333/465 72 (67–76)
S133G DE 8/75 1/31 32/81*** 4/278*** 45/465 10 (7–13)
P137T DE 8/75 1/31 30/81*** 4/278*** 43/465 9 (7–12)
K266T/N FG 8/75 1/31 30/81*** 4/278*** 43/465 9 (7–12)
A270P FG 8/75 1/31 30/81*** 4/278*** 43/465 9 (7–12)
D273N FG 8/75 1/31 30/81*** 3/278*** 42/465 9 (7–12)
V285G/A FG 9/75 1/31 34/81*** 7/278*** 51/465 11 (8–14)
I299M/L bG1 62/75 28/31 38/81* 211/278 339/465 73 (69–77)
T349N HI 1/75* 2/31 11/81 26/278 40/465 9 (6–12)
G352D HI 8/75 1/31 30/81*** 4/278*** 43/465 9 (7–12)
D357N HI 8/75 1/31 30/81*** 4/278*** 43/465 9 (7–12)
I386V a2 10/75 2/31 46/81*** 16/278*** 74/465 16 (13–20)
D394N a2-a3 14/75 2/31 45/81*** 10/278*** 71/465 15 (12–19)
N396D a3 15/75 2/31 46/81*** 10/278*** 73/465 16 (13–19)
18 L3M Nt 3/13 1/10 4/23 17 (5–39)
T88N bC-bD 10/13 3/10 13/23 57 (34–77)
A103V bD 2/13 1/10 3/23 13 (3–34)
Q273P FG 2/13 0/10 2/23 9 (1–28)
V323I bG2-bH1 4/13 0/10 4/23 17 (5–39)
45 S23N Nt-bB1 12/13 12/13 92 (64–100)
N55S BC 7/13 7/13 54 (25–81)
I140V DE 3/13 3/13 23 (5–54)
E287D FG 1/13 1/13 8 (0–36)
I303T bG1 4/13 4/13 31 (9–61)
N353T HI 1/13 1/13 8 (0–36)
S357G/N HI 11/13 11/13 85 (55–98)
Q366H HI-bI 7/13 7/13 54 (25–81)
DT499 Ct 11/13 11/13 85 (55–98)
DA500 Ct 11/13 11/13 85 (55–98)
DS501 Ct 11/13 11/13 85 (55–98)
a L1 region incorporating substitutions or deletions (D) within amino (Nt) and carboxy (Ct) terminii, external loops (BC, DE, EF, FG, HI), alpha helices (a) or beta sheets (b).
b Proportion of regional sequences harboring indicated mutation relative to total number of sequences with differences highlighted in bold type.
* p<0.05; (2-tailed Fisher’s exact test).
** p<0.01; (2-tailed Fisher’s exact test).
*** p<0.001 (2-tailed Fisher’s exact test).
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on the surface of the FG loop (Fig. 3A, 3B HPV31). There were too
few African and Asian sequences to ascertain the proportions of
their distribution outside of the Americas. HPV31 MAbs have been
shown to target both the EF and FG loops. MAb H31.A6 bound VLP
containing the HPV31 EF loop in a HPV16 backbone, but not the re-
ciprocal mutant (Carter et al., 2003). Three HPV31 MAbs have been
identiﬁed as targeting the FG loop, including an epitope encom-passing the T267A variant residue (Fleury et al., 2009), while an-
other study demonstrated that cross-reactive HPV16/HPV31
MAbs share a common binding motif in the FG loop (Carpentier
et al., 2005). The FG loop variants T267A and T274Nmay, therefore,
have an impact on the epitope conﬁguration of some HPV31-spe-
ciﬁc antibodies.
The reference sequence for HPV33 represented 48% (95% CI, 35–
62%) of sequences examined and was identical to both the consen-
AB
Fig. 3. Crystal model surface representation of variant amino acid residues. (A) top view (left panel) and side view (right panel) of HPV16 pentamer (PDB code: 2R5H) with
variable loops shaded as indicated. (B) Shannon entropy scores for indicated A9 HPV types are mapped onto top view of HPV16 pentamer structure according to the indicated
scheme. Only those variant amino acid residues located on the surface of the capsomer are shown. While all ﬁve monomers of the capsomer are pictured, and all appropriate
sites of variation are highlighted, only one of the ﬁve copies of a residue are indicated with the amino acid mutation (black arrows), and all the variations for a given HPV type
may not be indicated on the same monomer.
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variation in the HPV33 L1 protein, including variation in the BC
(T56N), DE (G133S, K135R), FG (T266K/N, G268E) loops and the
Ct (K495R) (Fig. 2, Table 1). Despite the number of individual var-
iant residues, the number of variant sequences containing multiple
variant sites was fairly limited (Supplementary Fig. S1). The majorvariant residues of HPV33 were dispersed across the surface of the
capsomer (Fig. 3A and B HPV33), including the tip of the BC loop, a
small cleft at the base of the BC and EF loops (adjacent to the FG
loop) and the capsomer lumen. The most common variant posi-
tions (T56N, G133S, T266K, K495R) were found in the Americas,
Asia and Africa, although the latter two regions were represented
A.I. Ahmed et al. / Infection, Genetics and Evolution 18 (2013) 151–159 157by too few sequences (n = 5 and 7, respectively) to evaluate their
proportionate distribution. Three HPV33 MAbs (H33.J3, H33.B6
and H33.E12) have been identiﬁed as binding conformational epi-
topes within the BC, DE and FG loops (Roth et al., 2006). H33.J3 ap-
pears to target a discrete epitope within the BC loop of HPV33 and
was able to neutralize an HPV16:HPV31BC hybrid and wild-type
HPV33 but not wild-type HPV16 (Roth et al., 2006). Naturally
occurring residue variations within the BC, DE and FG loops, as
highlighted in this study, may therefore affect recognition by these
MAbs and, by implication, neutralizing antibodies generated to the
HPV33 L1 protein.
The reference, consensus and pseudovirus sequences for HPV52
were identical, representing 81% (95% CI, 75–87%) of sequences
and could be found in the Americas, Asia and Africa. There were
four main sites of variation in the HPV52 L1 protein (Fig. 2), located
in the FG (Q282K) and HI (K355T, S358D/N) loops and the a4-bJ re-
gion (D448E) found on a limited number of variant sequences
(Supplementary Fig. S1). Three of these (Q282K, K355T, S358D/N)
appeared to form a distinct cluster along the edges of the FG/HI
loops (Fig. 3A, 3B HPV52). Overall, these variants were present in
<10% of sequences (Table 1) and tended to be underrepresented
in sequences from Asia. There were few data available on the spec-
iﬁcity of HPV52 MAbs (Rizk et al., 2008). HPV52 VLP incorporating
the BC loop of HPV16 reduced, but did not eliminate, the binding of
four HPV52 MAbs, suggesting that this region may contribute to
the formation of an immunodominant domain (Carter et al.,
2003). The implications of variation within the FG and HI loops,
as outlined herein, are uncertain. The Q282K substitution restores
a Lysine residue that, for HPV16 (K278) at least, is thought to be
important for cell binding via heparin moieties (Knappe et al.,
2007). No other HPV types exhibited signiﬁcant (P5%) variation
within these putative heparin-binding sites.
The reference sequence for HPV58 represented only 6% (95% CI,
4–9%) of sequences. The consensus sequence differed from the ref-
erence by L124F (DE loop) and I299M/L (bG1 region) substitutions,
represented 62% (95% CI, 58–67%) of sequences examined and
could be found in all four geographical regions. The pseudovirus
sequence for HPV58 was the same as the reference and therefore
did not represent the consensus of circulating sequences. Variation
across the L1 protein was greater for HPV58 than any of the types
evaluated (Fig. 2) and predominantly associated with the external
loops (p < 0.001). Variant residues were found in internal domains
including bG1 (I299M/L), a2 (I386V), a2-a3 (D394N), a3 (N396D)
and the DE (V118I, L124F, S133G, P137T), FG (K266T/N, A270P,
D273 N, V285G/A) and HI (T349 N, G352D, D357N) loops. These
variant residues could be found in various combinations within
21 distinct variant sequences (Supplementary Fig. S1). Most of
the surface-exposed variant residues formed part of distinct clus-
ters of sites between the bases of the BC and EF loops and the distal
portion of the FG and HI loops (Fig. 3A and B HPV58). The pentamer
lumen also exhibited a degree of variation. With the exceptions of
the L124F, I299M/L and T349N mutations the remainder were
highly overrepresented in African and underrepresented in Asian
sequences (Table 1). A limited number of HPV58 MAbs have been
generated and these appear to exhibit a range of target speciﬁcities
(Brendle et al., 2010) although detailed epitopes have not been
deﬁned.3.3. HPV18 and HPV45
There were few HPV18 (n = 23) and HPV45 (n = 13) full length
L1 sequences available for analysis. The majority of the HPV18
and all of the HPV45 sequences were from the Americas, with no
available sequences from Europe or Africa (Fig. 1), prohibiting an
evaluation of geographic distribution of individual variants.The reference sequence for HPV18 represented 39% (95% CI, 20–
61%) of sequences. The consensus sequence for HPV18 differed
from the reference by a T88N substitution (present in 57% of se-
quences) in the bC-bD region, although the consensus sequence it-
self was only represented by a single sequence. The pseudovirus
sequence for HPV18 was the same as the reference and therefore
did not represent the consensus sequence. The majority of substi-
tutions were located within internal structural domains (L3M,
A103V, V323I) (Fig. 2), with the exception of one substitution,
Q273P, found within the FG loop (Table 1). These variant residues
were found in a limited number of combinations (Supplementary
Fig. S1). HPV18 VLP used in the Cervarix vaccine appear to contain
the T88N, A103V and Q273P but not the L3M and V323I substitu-
tions (Deschuyteneer et al., 2010). HPV18 vaccine antibodies are
monitored by competition with MAb H18.J4 (Dias et al., 2005;
Giannini et al., 2006; Smith et al., 2008) which recognizes a pre-
dominantly type-speciﬁc conformational neutralizing epitope
(Smith et al., 2007).
The reference sequence for HPV45 represented only 1/13 se-
quences (8%; 95% CI, 2–36%). There were a number of variant res-
idues relative to the reference sequence (Fig. 2) including those in
the structural domains Nt-bB1 (S23N), bG1 (I303T), HI-b1 (Q366H),
Ct (D499–501) and the BC (N55S), DE (I140V), FG (E287D) and HI
(N353T, S357G/N) loops but too few sequences overall to evaluate
the proportions of these variants appropriately (Table 1). These
variant residues were found in a limited number of combinations
(Supplementary Fig. S1). The pseudovirus sequence for HPV45
was the same as the reference. MAbs raised against HPV45 VLP
are directed towards conformational epitopes and can be either
type-speciﬁc or cross-reactive (Smith et al., 2007), though the ex-
act epitope(s) are not available.4. Conclusions
The number of available full length L1 sequences for some of
the HPV types limited the precision of estimates around the pro-
portions of site-speciﬁc variation. Most A10 species group se-
quences were from Europe while the majority of the A7 and A9
species group sequences were from the Americas or Asia. There
was a paucity of African sequences overall and of European se-
quences representing A7 and A9 species group genotypes. In addi-
tion, it is possible that the deposition of sequences has been
skewed towards the reporting of more variant sequences rather
than sequences that match the reference. Taken together, any
empirical evaluation of site-speciﬁc residue variation will likely
be somewhat biased by the disparate distribution of the available
sequences, a common problem with this kind of assessment. Nev-
ertheless, the number of sequences was sufﬁcient to highlight the
representativeness, or not, of the reference and pseudovirus se-
quences and signiﬁcant sites of intra-type variation for further
study.
The reference sequence was the same as the consensus se-
quence for HPV6, HPV11, HPV33 and HPV52 but for the other types
represented a minority variant. The pseudovirus L1 sequence was
representative of the consensus sequence for HPV6, HPV11,
HPV16, HPV33 and HPV52. For the remainder (HPV18, HPV31,
HPV45 and HPV58) the pseudovirus sequence was based upon
the reference sequence and was therefore not representative of
the majority of circulating HPV sequences. The lack of representa-
tion of the consensus sequences in the pseudoviruses may not be a
signiﬁcant issue provided naturally occurring deviations do not
negatively impact the functional utility of the pseudovirus assay.
For studies of natural infection, therefore, it may be appropriate
to evaluate empirically the implications of these deviations from
the pseudovirus sequence.
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type, was high and localized to the external loops (p < 0.001; Sup-
plementary Fig. S2) as expected (Chen et al., 2000). A difference in
the intra-type entropy scores between the external loops and
internal structural regions was only found for HPV58, however,
reﬂecting both the high volume of available L1 sequences and
the degree of variation for this HPV type. Intra-type entropy was
more sporadic and generally of lower magnitude than similar eval-
uations for RNA viruses such as HIV-1 (Rhee et al., 2008; Woo et al.,
2010), Inﬂuenza (Huang et al., 2012) and Norovirus (Jin et al., 2011)
reﬂecting the excellent proof-reading capability of host cell poly-
merases and the apparent timescale in which these variants have
arisen (Chen et al., 2009).
Sites of variation for HPV6, HPV11, and to some extent for
HPV52, were rare or conﬁned to a limited number of internal res-
idues suggesting that the impact of these polymorphisms on recog-
nition by L1-speciﬁc antibodies is unlikely to be signiﬁcant. For
HPV16, the most common sites of variation (apart from the reci-
procal A266T variant) have already been evaluated (Pastrana
et al., 2001) and demonstrate a limited effect on antibody recogni-
tion. For the remaining HPV types, the degree of site-speciﬁc vari-
ation was high and in some cases within domains implicated in the
recognition by L1-speciﬁc antibodies. This was particularly evident
for HPV31, HPV33 and HPV58. For HPV31 and HPV33 the residues
exhibiting the highest degree of variation tended to be in discrete
sites while for HPV58 these residues appeared to be localized into
distinct clusters. Some HPV types exhibited a degree of variation
within the lumen of the capsomer which has potential implications
for the interaction with the minor capsid protein, L2 (Buck et al.,
2008).
The consequences of these polymorphisms for recognition by
antibodies elicited following natural infection or vaccination by
the current and next generation vaccines warrants further
investigation.
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